Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.

The addition of camrelizumab to neoadjuvant docetaxel plus carboplatin significantly increased the pCR rate in patients with stage II-III TNBC, with a manageable safety profile.

D. Jiao, X. Sun, J. Qiao et al. · 0 citations
Open access Sep 2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

BACKGROUND Bispecific antibody-drug conjugates (ADCs) may overcome limitations of monospecific ADCs. We report results from a phase 1b study of iza-bren, a first-in-class EGFR-HER3 bispecific ADC, in patients with heavily pretreated locally advanced or metastatic breast cancer. PATIENTS AND METHODS This multicenter s...

J. Zhang, Y. Meng, Y. Du et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.